European Journal of Nuclear Medicine

, Volume 11, Issue 1, pp 22–28 | Cite as

Radionuclide imaging of ovarian tumours with a radiolabelled (123I) monoclonal antibody (NDOG2)

  • Peter C. Jackson
  • Elizabeth M. Pitcher
  • John O. Davies
  • E. Rhys Davies
  • Christopher S. Sadowski
  • Gerald E. Staddon
  • Gordon M. Stirrat
  • Christopher A. Sunderland
Article

Abstract

The biodistribution of a radiolabelled monoclonal antibody (123I-NDOG2) was studied in patients with ovarian tumour. It was found that the uptake patterns in known tumour sites was variable and that the clearance of the agent from the vascular pool was due to renal excretion of the radionuclide and the redistribution of the radioactively labelled compound into other compartments. The mean (±SD) plasma clearance time was 20.8 (±2.3) h and the ratios of target (tumour) to background (thigh) ranged between 1.4 and 4.8. The ratio between the plasma radioactivity at either 3.5 or 20 h after administration was calculated relative to the initial plasma radioactivity. These values (0.79 and 0.48, respectively) were incorporated into an image-subtraction technique that allowed for redistribution outside the vascular pool. A whole-body dose equivalent to 16.3 μSv MBq-1 (60.4 mrem.mCi-1) was calculated.

Key words

Radioimmunodetection monoclonal antibody ovarian tumour image subtraction 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Carroll MJ, Flatman WD, Nimmon CC, Granowska M, Britton KE (1984) Congruent image registration as a prerequisite for detecting sequential changes during radioimmunoscintigraphy'. (Abstr) Nucl Med Commun 5:P230-P231Google Scholar
  2. Chatal JF, Saccavini JC, Fumoleau P, Douilland JY, Curtet C, Kremer M, Le Mevel B, Koprowski H (1985) Immunoscintigraphy of colon carcinoma. J Nucl Med 25:307–314Google Scholar
  3. Davies JO, Davies ER, Howe K, Jackson PC, Pitcher EM, Sadowski C, Stirrat GM, Sunderland CA (1984) Radionuclide imaging of ovarian tumours with 123I labelled monoclonal antibody (NDOG2) directed against placental alkaline phosphatase'. Br J Obstet Gynaecol 92:277–286Google Scholar
  4. Dillman LT, Van der Lage FC (1975) Radionuclide decay, schemes and nuclear parameters for use in radiation-dose estimation. Medical Internal Radiation Dose Committee: pamphlet no. 10. Society of Nuclear Medicine, New YorkGoogle Scholar
  5. Fairweather DS, Bradwell AR, Dykes PW, Vaughan AT, Watson-James SF, Chandler S (1983) Improved tumour localisation using indium-111 labelled antibodies. Br Med J 287:167–170Google Scholar
  6. Granowska M, Shepherd J, Mather S, Carroll MJ, Flatman WD, Nimmon CC, Taylor-Papadimitriou J, Ward B, Horne T, Britton KE (1984) A prospective study of radioimmunoscintigraphy in ovarian cancer. (Abstr) Nucl Med Commun 5:P236Google Scholar
  7. Green AJ, Begent RHJ, Keep PA, Bagshawe KD (1984) Analysis of radioimmunodetection of tumours by the subtraction technique. J Nucl Med 25:96–100Google Scholar
  8. International Commission on Radiological Protection (1977) Recommendations of the Internal Commission on Radiological Protection 1977: ICRP publication 26. Pergamon Press, OxfordGoogle Scholar
  9. McLaughlin PJ, Gee H, Johnson PM (1983) Placental-type alkaline phosphatase in pregnancy and malignancy serum: specific estimation using an antibody in a solid phase enzyme immunoassay. Clin Chim Acta 130:199–209Google Scholar
  10. Rankin EM, McVie JG (1983) Radioimmunodetection of cancer: problems and potential. Br Med J 287:1402–1404Google Scholar
  11. Schlumberger M, Van Herle AJ, Di Paola R, Vignal A, Di Paola M, Kahn E, Tubiana M (1982) In vivo localisation of radiolabelled antibodies to rat thyroglobulin in the 1-1C2 rat thyroid transplantable tumour. Nucl Med Commun 3:4–12Google Scholar
  12. Slack N, Rainsbury RM, Westwood JH, Coombes RC, Neville AM, Ott RJ, Kalirai TS, McCready VR, Gazet JC (1984) Comparison between monoclonal antibody images and conventional imaging techniques in the detection of skeletal metastases from breast carcinoma. (Abstr) Nucl Med Commun 5:P236Google Scholar
  13. Smith T, Veall N, Altman DG (1981) Dosimetry of renal radiopharmaceuticals: the importance of bladder radioactivity and a simple aid for its estimation. Br J Radiol 54:961–965Google Scholar
  14. Snyder WS, Ford MR, Warner GG, Watson SB (1975) “S” Absorbed dose per unit accumulated activity for selected radionuclides and organs. Medical Internal Radiation Dose Committee: pamphlet no. 11. Society of Nuclear Medicine. New YorkGoogle Scholar
  15. Sunderland CA, Davies JO, Stirrat GM (1984) Immunohistology of normal and ovarian cancer tissue with a monoclonal antibody to placental alkaline phosphatase. Cancer Res 44:4496–4502Google Scholar
  16. Wong DW, Dhawan VK, Tanaka T, Mishkin FS, Reese IC, Thadepalli H (1982) Imaging endocarditis with Tc-99m labelled antibody — an experimental study: concise communication. J Nucl Med 23:229–234Google Scholar

Copyright information

© Springer-Verlag 1985

Authors and Affiliations

  • Peter C. Jackson
    • 1
  • Elizabeth M. Pitcher
    • 1
  • John O. Davies
    • 1
  • E. Rhys Davies
    • 3
  • Christopher S. Sadowski
    • 4
  • Gerald E. Staddon
    • 1
  • Gordon M. Stirrat
    • 2
  • Christopher A. Sunderland
    • 2
  1. 1.Department of Medical PhysicsBristol General HospitalBristolUnited Kingdom
  2. 2.Department of Obstetrics and GynaecologyBristol Maternity HospitalBristolUnited Kingdom
  3. 3.Department of RadiodiagnosisBristol Royal InfirmaryBristolUnited Kingdom
  4. 4.Pharmacy DepartmentBristol General HospitalBristolUnited Kingdom

Personalised recommendations